InflaRx (IFRX) Stock Forecast & Price Target

InflaRx is viewed favorably because izicopan could enter a validated C5aR market where Tavneos has already proven commercial demand, generating $643M in 2025 worldwide sales, while also exposing clear shortcomings in safety, monitoring burden, and dosing complexity. The thesis is strengthened by izicopan’s differentiated profile, including no SAEs or TEAEs in more than 180 dosed subjects, faster target saturation, and better PK/PD than avacopan, with physician survey data showing 70% would switch to an izicopan-like profile and 92% expect class prescribing to rise. Additional upside comes from expansion optionality into renal indications and the company’s view that regulatory and data-integrity issues around Tavneos could shift share materially toward a safer oral successor.

InflaRx is facing a fundamentally fragile setup because GOHIBIC (vilobelimab) has been effectively wound down commercially in the U.S., leaving only reactive orderability and making any future U.S. or EU effort dependent on a partner. With only ~€29K revenue against ~€18.0M of SG&A expense in 2025, the business shows severe operating leverage problems, and management itself expects a “very significant reduction” in marketing and sales costs in 2026+ because there is little active commercialization to support. Its broader pipeline remains highly uncertain due to long development timelines, likely need for additional financing, limited differentiation versus established AAV therapies, and meaningful patent and competitive risks that could prevent durable value creation.